Xin Lang Cai Jing·2026-01-12 10:33Group 1 - The core viewpoint of the news is that Junshi Biosciences has shown significant trading activity, with a notable increase in stock price and substantial financing and margin trading data indicating a high level of investor interest [1][2] Group 2 - On January 9, Junshi Biosciences' stock price increased by 4.09%, with a trading volume of 520 million yuan [1] - The financing buy-in amount for Junshi Biosciences on the same day was 47.67 million yuan, while the financing repayment was 55.29 million yuan, resulting in a net financing outflow of 7.62 million yuan [1] - As of January 9, the total financing and margin trading balance for Junshi Biosciences was 1.344 billion yuan, with the financing balance accounting for 4.42% of the circulating market value, indicating a high level compared to the past year [1] - In terms of margin trading, on January 9, Junshi Biosciences had a margin repayment of 5,125 shares and a margin sell-out of 3,000 shares, with the sell-out amount calculated at 117,600 yuan [1] - The margin balance was 15.43 million yuan, exceeding the 90th percentile level over the past year, indicating a high level of short selling activity [1] Group 3 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2] - As of September 30, the number of shareholders for Junshi Biosciences was 35,900, an increase of 15.17% from the previous period, while the average circulating shares per person decreased by 12.96% [2] - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a year-on-year increase of 35.72% [2] - Among the top ten circulating shareholders, E Fund's Science and Technology Innovation Board 50 ETF held 19.39 million shares, a decrease of 2.82 million shares from the previous period [2] - Another major shareholder, Huaxia's Science and Technology Innovation Board 50 Component ETF, held 18.97 million shares, down by 1.07 million shares from the previous period [2]